Impact of menopausal symptoms on quality of life 6 months after systemic breast cancer treatment: results from the Shanghai Breast Cancer Survival Study

被引:16
作者
Dorjgochoo, Tsogzolmaa [1 ]
Kallianpur, Asha [1 ]
Zheng, Ying [2 ]
Gu, Kai [2 ]
Chen, Zhi [1 ]
Zheng, Wei [1 ]
Lu, Wei [2 ]
Shu, Xiao Ou [1 ]
机构
[1] Vanderbilt Univ, Sch Med,Med Ctr, Dept Med,Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth,Vanderbilt Ingram Canc Ctr, Nashville, TN 37203 USA
[2] Shanghai Inst Prevent Med, Shanghai 200336, Peoples R China
基金
美国国家卫生研究院;
关键词
Breast cancer; Quality of life; Menopausal symptoms; MOSQOL74; SF36; Systemic treatment; China; POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; CHINESE WOMEN; HEALTH SURVEY; HOT FLASHES; PREVALENCE; DIAGNOSIS; AGE; CARCINOMA; CHEMOTHERAPY;
D O I
10.1007/s10549-009-0434-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Menopausal symptoms (MPS) after breast cancer treatment are associated with reduced health-related quality of life (QOL) among Caucasian women. Little is known about whether MPS similarly impact QOL in Asian women with breast cancer. QOL was assessed by using the generic quality of life instruments, Medical Outcome Study of Quality of Life Inventory (MOSQOL-74) or Short Form-36 Health Survey (SF-36) in 4,976 Chinese participants of the Shanghai Breast Cancer Survival Study who were treated for incident, non-metastatic breast cancer within the 6 months before the study interview. Relationships between MPS and QOL were assessed by multiple linear regression, controlling for potential confounders. About 71.4% of study participants experienced MPS, including hot flashes, night sweats, vaginal dryness, depressed mood, and/or dry skin. Women with MPS reported lower overall QOL than women without MPS [mean scores 61.0 vs. 64.0, respectively (MOSQOL-74) and 54.9 vs. 66.9, respectively (SF-36); P < 0.01]. Adjusted mean differences (beta) in overall QOL in the presence and absence of MPS were -3.1 (95% CI -3.8, -2.4) with the MOSQOL-74 and -12.3 (95% CI -13.8, -10.9) with the SF-36. Women with any MPS had lower scores for the MOSQOL-74 physical and psychological domains and for the SF-36 social and emotional subscales than those without MPS (P < 0.05 for all). Having several MPS predicted poorer QOL in all domains measured regardless of the instrument used (P (trend) < 0.01 for all). Our study indicates that in Chinese women recently treated for breast cancer, MPS adversely impacts QOL. Actively soliciting and treating MPS in these women should significantly improve their QOL.
引用
收藏
页码:725 / 735
页数:11
相关论文
共 47 条
[1]
[Anonymous], 2005, NIH Consens State Sci Statements, V22, P1
[2]
[Anonymous], 1992, Measuring functioning and well-being: The medical outcomes study EApproach
[3]
A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis [J].
Arndt, Volker ;
Stegmaier, Christa ;
Ziegler, Hartwig ;
Brenner, Hermann .
CANCER, 2006, 107 (10) :2496-2503
[4]
Factors affecting baseline quality of life in two international adjuvant breast cancer trials [J].
Bernhard, J ;
Hürny, C ;
Coates, AS ;
Peterson, HF ;
Castiglione-Gertsch, M ;
Gelber, RD ;
Galligioni, E ;
Marini, G ;
Thürlimann, B ;
Forbes, JF ;
Goldhirsch, A ;
Senn, HJ ;
Rudenstam, CM .
BRITISH JOURNAL OF CANCER, 1998, 78 (05) :686-693
[5]
Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group study 9401 [J].
Brandberg, Y ;
Michelson, H ;
Nilsson, B ;
Bolund, C ;
Erikstein, B ;
Hietanen, P ;
Kaasa, S ;
Nilsson, J ;
Wiklund, T ;
Wilking, N ;
Bergh, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3659-3664
[6]
The impact of age on Health-Related Quality of Life (HRQoL) and symptoms among postmenopausal women with breast cancer receiving adjuvant chemotherapy [J].
Browall, Maria M. ;
Ahlberg, Karin M. ;
Persson, Lars-Olof G. ;
Karlsson, Per O. ;
Danielson, Ella B. .
ACTA ONCOLOGICA, 2008, 47 (02) :207-215
[7]
Byar Katherine L, 2006, Oncol Nurs Forum, V33, pE18, DOI 10.1188/06.ONF.E18-E26
[8]
Carpenter JS, 1998, CANCER-AM CANCER SOC, V82, P1682, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.3.CO
[9]
2-8
[10]
A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383